Shiseido has signed a binding agreement to sell its Chinese subsidiary Shiseido Liyuan Cosmetics (SLC) to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. SLC makes and sells the Aupres brand in China, and the transaction covers the entire company. Financial terms were not disclosed.
The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. It is part of Shiseido’s 2030 Medium-Term Strategy, under which the Japanese group aims to improve profitability and capital efficiency and direct management resources toward businesses where it sees the strongest competitive advantage.
Why Shiseido is divesting
Shiseido said SLC requires continued investment in product innovation and digital capabilities. Selling the unit will allow the group to concentrate on priority brands and higher-growth opportunities. The company described China as a strategically important and attractive market, while noting that competition is evolving with e-commerce expansion, changing consumer behavior and the arrival of diverse market participants.
SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. It has sold Aupres, described as a C-beauty brand, since 1994. The existing joint venture agreement was due to expire in December 2026, and the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership before the sale.
Ownership and handover
Under the transaction, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles. A limited partnership set up mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment.
Shiseido will license the intellectual property rights IDG needs to operate the business. For a specified period after the transfer, it will also provide support on new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. Shiseido said the arrangements are intended to maintain SLC’s innovation capabilities, product quality and business continuity, and it believes independent operation under IDG can support SLC’s sustainable growth and brand value.
Profit recovery context
The divestment follows Shiseido’s third-quarter 2026 results, which showed core operating profit up 124.3% year on year to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales rose 0.7%. Shiseido raised its full-year core operating profit forecast to ¥87 billion (US$546 million) from ¥59 billion (US$433 million).
The sale therefore arrives as Shiseido is trying to lift profitability while retaining a China strategy focused on selected priorities. The agreement remains subject to approvals, and the company has not disclosed the consideration or the expected financial impact of the transaction.
